SEC Form 4 · accession 0001593968-19-000310
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard C Williams
Director
Period of report
Jan 30, 2019
Accepted (ET)
Feb 1, 2019 · 9:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.09 | Jan 30, 2019 | A | 30,000 | A | — | Jan 30, 2029 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The option vests monthly over a period of twelve months commencing on the grant date. The option is granted pursuant to the 2009 Equity Incentive Plan and is subject to other provisions as are set forth in the option agreement relating to such grant under the plan.